AEMD

Aethlon Medical, Inc. (AEMD) | Rumor.io

Aethlon Medical

AEMD

Attention (50-day avg)0%

Attention rank (50-day avg)#740

Bullish sentiment (50-day avg)74%

Price to earnings ratio0.01

Market capitalization4.5M

Earnings per share-14.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-7.2M

Social

What share of all stock conversation is about AEMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% -0.02	0.01% +0	0% 0

Sep 18

Aethlon Medical ($AEMD) has seen a significant price increase, with a +379% gain in one day, making it the top gainer in the US market.
The company's merger announcement is cited as a catalyst for the price surge, and analysts are bullish on the stock, with an average price target of $13.25 (+95.43%).
Aethlon Medical's balance sheet shows a positive net cash position, with $4.57M in net cash, but the company continues to report negative cash flow, with an operating cash flow of -$7.18M.

Generated by AI

Sentiment

Of the messages about AEMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +29.72	73.24% -1.62	78.22% -7.07
Bearish	0%	0% -29.72	26.76% +1.62	21.78% +7.07

Bullish· Sep 18

Aethlon Medical ($AEMD) has experienced a significant price increase, with a 379% gain, making it the top gainer in the US market today.
The company's merger announcement with North Immunology has been a catalyst for its parabolic price rise, with a 344% increase.
Aethlon Medical's balance sheet shows a positive net cash position, with $4.57M in cash and a 48.31% increase in net cash, providing a strong foundation for future growth.

Bearish· Sep 17

The asset's price is highly susceptible to manipulation due to its micro-float with a crowded short side, which can lead to sudden and extreme price movements.
The company's recent actions, such as the reverse merger and financing, may not be accurately reflected in the current market price, making it a potentially good shorting opportunity.
The asset's short interest is high, with 461K shares reported, indicating a large number of investors are betting against the stock's success, which could contribute to further price declines.

Generated by AI

Topics

Of the messages about AEMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	71.76%	4.21%
Technical Analysis	0%	0%	18.57%	1.67%
Analysts	0%	0%	2.71%	93.42%
Macro	0%	0%	1.74%	0.33%
Controversies	0%	0%	5.22%	0.33%
Earnings	0%	0%	0%	0.03%

Earnings· Feb 1

Aethlon Medical, Inc. ($AEMD) has released its earnings report.
$AEMD is scheduled to release its earnings on February 1 after the close.
Investors are considering buying or selling $AEMD during its earnings release.

Announcements· Sep 17

Aethlon Medical, Inc. ($AEMD) has agreed to an all-stock merger with North Immunology in a deal expected to bring $180 million in gross proceeds.
The combined company will be renamed and listed on the Nasdaq as $NRTX, with pre-merger Aethlon stockholders expected to own approximately 4.75% of the new company.
The merger is expected to fund the combined company's operations into the second half of 2028, with the lead candidate NOR-101 heading toward Phase 1 in Q1 2027.

Technical Analysis· Sep 17

The stock $AEMD has shown strong momentum, with a 392% increase and a strong volume spike at the lows in late August.
The stock's chart has a hidden pattern, with a volume-backed break and hold above $7.60–$7.65 serving as confirmation, and a potential target of $7.80–$8.00.
The stock has formed higher lows, with a potential reversal and a test of the recent high of $9.50, and may break through to new highs or pull back to $12+.

Generated by AI

Community

Of the messages about AEMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	72.73%	11.85%	34.85%	10.92%
Newcomers	27.27%	88.15%	65.15%	89.08%

Regulars· Sep 18

Aethlon Medical, Inc. ($AEMD) has announced a definitive merger agreement with North Immunology, with the combined company operating as North Immunology, Inc. ($NRTX) post-completion.
Short interest in $AEMD has seen a massive 609.43% increase, with 461,661 shares sold short, indicating that short sellers have aggressively piled into the stock recently.
$AEMD's device has shown a reduction in EVs, which is seen as potentially beneficial in oncology and a range of diseases, with the stock trending with force today.

Newcomers· Sep 18

The price of AEMD has surged by 379% in a single day, making it the top gainer in the US market, and some analysts are predicting a price target of $13.25, a 95.43% increase from the current price.
Aethlon Medical's merger announcement has been cited as a catalyst for the stock's parabolic rise, and some analysts are concerned about the potential for massive dilution due to North investors' 95% future ownership stake.
Despite the stock's recent surge, Aethlon Medical continues to report negative cash flow, and its free cash flow remains negative despite a positive net cash position, raising questions about the company's long-term financial sustainability.

Generated by AI

News

North Immunology To Go Public Via Reverse Merger With Aethlon Medical (NASDAQ:AEMD)

North Immunology will emerge into the public biotech world through a reverse merger with Aethlon Medical (AEMD).

11d agoSeeking Alpha

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

11d agoMorningstar

Aethlon Stock Pulls Back: What's Going On?

11d agoBenzinga

Aethlon Medical stock merger with North Immunology, H.C. Wainwright holds neutral

11d agoInvesting.com

Aethlon Medical Q1 2027 Earnings Call Transcript

12d agoBenzinga

AEMD, OKLO, DAIC, XENE, MRNA: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)

12d agoBenzinga

Also Discussed

Investors talking about AEMD also mention

#	Name	Attention
1	GeoVax Labs, Inc.GOVX	0%+0
2	AMED - Amedisys, Inc.	——
3	Nanoviricides Inc.NNVC	0%0
4	BioAffinity Technologies Inc.BIAF	0%+0
5	iBio, Inc.IBIO	0%0
6	TBLT - ToughBuilt Industries, Inc.	——
7	Veea Inc.VEEA	0%0
8	Versus Systems Inc.VS	0%0
9	MOND - Mondee Holdings, Inc.	——
10	Generation Income Properties Inc.GIPR	0%0

Aethlon Medical, Inc.

Healthcare
Medical Devices

Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids. The company’s work spans applications in cancer care, life-threatening viral infections, and organ transplantation, with a broader emphasis on addressing unmet needs in medical treatment and biodefense. Aethlon Medical combines device-based therapy and filtration science to support clinical research in areas where current options remain limited. Headquartered in San Diego, California, the company operates as a specialized player in the healthcare sector, concentrating on advanced therapeutic devices rather than broad pharmaceutical products.

Website

Location

11555 Sorrento Valley Road

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about AEMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% -0.02	0.01% +0	0% 0

Sep 18

Aethlon Medical ($AEMD) has seen a significant price increase, with a +379% gain in one day, making it the top gainer in the US market.
The company's merger announcement is cited as a catalyst for the price surge, and analysts are bullish on the stock, with an average price target of $13.25 (+95.43%).
Aethlon Medical's balance sheet shows a positive net cash position, with $4.57M in net cash, but the company continues to report negative cash flow, with an operating cash flow of -$7.18M.

Generated by AI

Sentiment

Of the messages about AEMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +29.72	73.24% -1.62	78.22% -7.07
Bearish	0%	0% -29.72	26.76% +1.62	21.78% +7.07

Bullish· Sep 18

Aethlon Medical ($AEMD) has experienced a significant price increase, with a 379% gain, making it the top gainer in the US market today.
The company's merger announcement with North Immunology has been a catalyst for its parabolic price rise, with a 344% increase.
Aethlon Medical's balance sheet shows a positive net cash position, with $4.57M in cash and a 48.31% increase in net cash, providing a strong foundation for future growth.

Bearish· Sep 17

The asset's price is highly susceptible to manipulation due to its micro-float with a crowded short side, which can lead to sudden and extreme price movements.
The company's recent actions, such as the reverse merger and financing, may not be accurately reflected in the current market price, making it a potentially good shorting opportunity.
The asset's short interest is high, with 461K shares reported, indicating a large number of investors are betting against the stock's success, which could contribute to further price declines.

Generated by AI

Topics

Of the messages about AEMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	71.76%	4.21%
Technical Analysis	0%	0%	18.57%	1.67%
Analysts	0%	0%	2.71%	93.42%
Macro	0%	0%	1.74%	0.33%
Controversies	0%	0%	5.22%	0.33%
Earnings	0%	0%	0%	0.03%

Earnings· Feb 1

Aethlon Medical, Inc. ($AEMD) has released its earnings report.
$AEMD is scheduled to release its earnings on February 1 after the close.
Investors are considering buying or selling $AEMD during its earnings release.

Announcements· Sep 17

Aethlon Medical, Inc. ($AEMD) has agreed to an all-stock merger with North Immunology in a deal expected to bring $180 million in gross proceeds.
The combined company will be renamed and listed on the Nasdaq as $NRTX, with pre-merger Aethlon stockholders expected to own approximately 4.75% of the new company.
The merger is expected to fund the combined company's operations into the second half of 2028, with the lead candidate NOR-101 heading toward Phase 1 in Q1 2027.

Technical Analysis· Sep 17

The stock $AEMD has shown strong momentum, with a 392% increase and a strong volume spike at the lows in late August.
The stock's chart has a hidden pattern, with a volume-backed break and hold above $7.60–$7.65 serving as confirmation, and a potential target of $7.80–$8.00.
The stock has formed higher lows, with a potential reversal and a test of the recent high of $9.50, and may break through to new highs or pull back to $12+.

Generated by AI

Community

Of the messages about AEMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	72.73%	11.85%	34.85%	10.92%
Newcomers	27.27%	88.15%	65.15%	89.08%

Regulars· Sep 18

Aethlon Medical, Inc. ($AEMD) has announced a definitive merger agreement with North Immunology, with the combined company operating as North Immunology, Inc. ($NRTX) post-completion.
Short interest in $AEMD has seen a massive 609.43% increase, with 461,661 shares sold short, indicating that short sellers have aggressively piled into the stock recently.
$AEMD's device has shown a reduction in EVs, which is seen as potentially beneficial in oncology and a range of diseases, with the stock trending with force today.

Newcomers· Sep 18

The price of AEMD has surged by 379% in a single day, making it the top gainer in the US market, and some analysts are predicting a price target of $13.25, a 95.43% increase from the current price.
Aethlon Medical's merger announcement has been cited as a catalyst for the stock's parabolic rise, and some analysts are concerned about the potential for massive dilution due to North investors' 95% future ownership stake.
Despite the stock's recent surge, Aethlon Medical continues to report negative cash flow, and its free cash flow remains negative despite a positive net cash position, raising questions about the company's long-term financial sustainability.

Generated by AI

Aethlon Medical

Social

Sep 18

Bullish· Sep 18

Bearish· Sep 17

Earnings· Feb 1

Announcements· Sep 17

Technical Analysis· Sep 17

Regulars· Sep 18

Newcomers· Sep 18

North Immunology To Go Public Via Reverse Merger With Aethlon Medical (NASDAQ:AEMD)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Stock Pulls Back: What's Going On?

Aethlon Medical stock merger with North Immunology, H.C. Wainwright holds neutral

Aethlon Medical Q1 2027 Earnings Call Transcript

AEMD, OKLO, DAIC, XENE, MRNA: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)

Also Discussed

Aethlon Medical, Inc.

Company Information

Location

North Immunology To Go Public Via Reverse Merger With Aethlon Medical (NASDAQ:AEMD)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Stock Pulls Back: What's Going On?

Aethlon Medical stock merger with North Immunology, H.C. Wainwright holds neutral

Aethlon Medical Q1 2027 Earnings Call Transcript

AEMD, OKLO, DAIC, XENE, MRNA: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)

Also Discussed

Social

Sep 18

Bullish· Sep 18

Bearish· Sep 17

Earnings· Feb 1

Announcements· Sep 17

Technical Analysis· Sep 17

Regulars· Sep 18

Newcomers· Sep 18